JS105 Clinical Trials
2 recruitingDrug
Phase 31Phase 11Phase 21
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd.312 enrolled2 locationsNCT07207070
Recruiting
Phase 1Phase 2
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Advanced Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.306 enrolled1 locationNCT06208410